Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
75 hedge funds and large institutions have $221M invested in Kindred Biosciences, Inc. in 2019 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 12 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
0% more funds holding
Funds holding: 75 → 75 (0)
5% less capital invested
Capital invested by funds: $233M → $221M (-$12.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.61M |
| 2 |
BlackRock
New York
|
+$3.67M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.66M |
| 4 |
AI
Ariel Investments
Chicago,
Illinois
|
+$1.99M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7.02M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.09M |
| 3 |
Millennium Management
New York
|
-$771K |
| 4 |
PVAM
Pacific View Asset Management
San Francisco,
California
|
-$596K |
| 5 |
Two Sigma Investments
New York
|
-$519K |
KIN Hedge Fund Activity: Q2 2019 in Review
75 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2019, worth a combined $221M — down 5.3% from $233M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KIN positions and 12 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $6.61M. The largest seller was Deutsche Bank, cutting an estimated $7.02M.
- 75 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $221M of Kindred Biosciences, Inc. stock for Q2 2019, down 5.3% quarter-over-quarter.
- 14 funds opened new Kindred Biosciences, Inc. positions in Q2 2019 and 12 closed out, a net change of +2 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2019 was Morgan Stanley, an estimated $6.61M added.
- The largest Kindred Biosciences, Inc. seller in Q2 2019 was Deutsche Bank, an estimated $7.02M sold.
Based on aggregated 13F filings for Q2 2019.